New pain pathways are being identified in osteoarthritis. This is the most common type of arthritis in North America. Keeping active and weight loss are important in slowing the progression of osteoarthritis. For some people, joint damage can be significant and yet they may not be able to have joint replacement surgery. Many new treatments are being researched to address pain being generated by the joints specifically. One area of research is aimed at reducing NGF (nerve growth factor). This type of treatment may also be of great help in reducing bone cancer pain, diabetic neuropathy, low back pain and interstitial cystitis. Stay tuned as this research moves forward.
Our pharmacist, Carolyn Whiskin, recently returned from The American College of Rheumatology Conference, the largest international meeting held for rheumatology. Over 15,000 health professionals from around the world specializing in research and the care of people with arthritis were in attendance. Today’s blog post is one several with information Carolyn learned at the Conference.
Saphnelo (anifrolumab) is a one-of-a-kind therapy by AstraZeneca for the treatment of moderate to severe…
On December 4, 2023, Health Canada approved Pfizer’s Litfulo (ritlecitinib). Litfulo is a once-daily oral…
Infliximab is a protein-based medication referred to as a biologic that treats many immune-mediated conditions. …
On October 3rd, 2023, Health Canada approved Eli Lilly’s newest biologic for the treatment of…
As February is heart month, today is an excellent occasion to really show why we love our hearts and…
To better serve our Hamilton and area patients, we have expanded and moved our Stoney…